Surgalign Announces Partnership –

Surgalign Coflex Patient Access Assistance Program® Interlaminar stabilization® and
SIMmetry® SI joint fusion systems

DEERFIELD, Ill., July 14 10, 2022 (GLOBE NEWSWIRE) — Surgalign Holdings, Inc., (SRGA), a global medical technology company focused on raising the standard of care by driving the evolution of digital health, announced that PRIA Healthcare will serve as a strategic partner in support of the recent launch of Surgalign Patient Access Program.

The goal of the Surgalign Patient Access Program is to help patients gain greater access to medical technologies that generate better outcomes, such as the Coflex Interlaminar Stabilization and SImmetry Sacroiliac (SI) Joint Fusion Systems. of the society. As a tireless patient advocate, PRIA brings to the collaboration more than 10 years of experience partnering with MedTech companies to improve patient access to the latest medical technologies.

Terry Rich, President and CEO of Surgalign, said, “Our vision at Surgalign is to achieve optimal patient outcomes while advancing the standard of spine care. We partnered with PRIA because of their extensive experience in advocating for patients to benefit from favorable medical coverage. Ultimately, this program will expand patient access to procedures and devices such as the Coflex Interlaminar Stabilization Systems and SImmetry SI Joint Fusion.

The Coflex Interlaminar Stabilization Device is a lumbar motion preserving solution that maintains spinal stability after direct surgical decompression while preserving more natural motion. Coflex has level 1 clinical data from a randomized controlled trial used for PMA approval which was reported in the International Journal of Spine Surgery1. Additionally, the Coflex device appears in more than 90 peer-reviewed publications and has been implanted more than 175,000 times worldwide.

The SImmetry SI Joint Fusion System is the only lateral approach SI procedure that follows the orthopedic principles of joint decortication, bone grafting and fixation, to create the best possible environment for performing true arthrodesis. The recently published SImmetry EVoluSIon (EVSI) study, one of the largest SI joint fusion studies conducted to date, showed statistically significant improvements in pain and disability, as well as a statistically significant reduction significant number of patients using opioids at 12 months.2.

“We look forward to seeing the positive impact of PRIA’s streamlined authorization and appeal process on the challenges patients face obtaining medical coverage for necessary care,” added Scott Durall, Chief Commercial Officer of Surgalign. . “This partnership underscores our commitment to supporting our community of physicians and patients by educating payers on the clinical benefits of new therapies such as Coflex and SImmetry, which deliver positive clinical outcomes for patients.

1 Musacchio MJ, Lauryssen C, Davis RJ, et al. Evaluation of decompression and interlaminar stabilization versus decompression and fusion for the treatment of lumbar spinal stenosis: 5-year follow-up of a prospective, randomized, controlled trial. Int. J. Spine surgery. 2016 Jan 26;10:6. Doi: 10.14444/3006. eCollection 2016.
2 Kucharzyk D, Colle K, Boone C, Araghi A. Clinical results after minimally invasive sacroiliac joint fusion with decortication: EVoluSIon clinical study. Int. J. Spine surgery. 2022, 16 (1) 168-175. doi:

About Surgalign Holdings, Inc.
Surgalign Holdings, Inc. is a global medical technology company committed to the promise of digital health to drive transformation in the surgical landscape. Uniquely aligned and resourced to advance the standard of care, the company develops technologies that physicians and other healthcare providers will turn to for what is truly possible for their patients. Surgalign is focused on developing solutions that predictably deliver superior clinical and economic outcomes. Surgalign markets its products in the United States and in more than 50 countries around the world through a growing network of leading independent distributors. Surgalign is headquartered in Deerfield, IL, with shopping, innovation and design centers in San Diego, California, Warsaw and Poznan, Poland, and Wurmlingen, Germany. Learn more at and connect on LinkedIn and Twitter.

About PRIA Health
Since 2012, PRIA Healthcare has been a national leader in healthcare reimbursement and market access in the United States. Led by a team of industry veterans, PRIA is committed to ensuring the latest medical technologies and procedures are available to patients both during clinical trials and through product commercialization. PRIA works diligently to influence payers to establish patient access to life-changing devices, therapies, treatments and procedures by leveraging clinical data, patient and physician rights.

Forward-looking statement
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements are based on management’s current expectations, estimates and projections regarding our products, our company and our industry, the beliefs of our management and certain assumptions made by our management. Words such as “anticipates”, “expects”, “intends”, “plans”, “believes”, “seeks”, “estimates” and other variations of these words and similar expressions are intended to identify such forward-looking statements. These statements are not guarantees of future performance and are subject to risks and uncertainties, including the risks described in our public filings with the United States Securities and Exchange Commission (SEC). Our actual results may differ materially from the anticipated results reflected in these forward-looking statements. Copies of the Company’s filings with the SEC may be obtained by contacting the Company or the SEC or by visiting Surgalign’s website at or the SEC’s website at


Comments are closed.